Skip to main content

Clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension


Pulmonary arterial hypertension is a type of malignant pulmonary vascular disease, which is mainly caused by the increase of pulmonary vascular resistance due to the pathological changes of the pulmonary arteriole itself, which eventually leads to right heart failure and death. As one of the diagnostic indicators of hemodynamics, pulmonary vascular resistance plays an irreplaceable role in the pathophysiology, diagnosis and treatment of pulmonary arterial hypertension. It provides more references for the evaluation of pulmonary arterial hypertension patients. This article summarizes the clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension.

Peer Review reports


Pulmonary hypertension is a common pulmonary vascular disease, which is caused by various causes of increased pulmonary artery pressure. Pulmonary arterial hypertension (PAH), as the first category in the clinical classification of pulmonary hypertension, refers to increased pressure in the solitary pulmonary artery, while the pressure in the left atrium and pulmonary veins are normal. It is mainly caused by the increase of pulmonary vascular resistance (PVR) caused by the pathology of the pulmonary arterioles itself, and pulmonary hypertension caused by chronic respiratory diseases, chronic thromboembolic diseases and other unknown factors are excluded. Idiopathic pulmonary arterial hypertension is a subtype of PAH, a type of malignant pulmonary vascular disease of unknown cause, which is mainly characterized by progressive increase in PVR [1, 2]. PVR is a static index for evaluating pulmonary circulation hemodynamics. The unequal branch of the pulmonary artery determines the difference in impedance from the main pulmonary artery to the distal vascular bed [3]. PVR was originally based on Poiseuille's law, which describes the pressure loss caused by fluid flowing through a thin tube, which is proportional to the product of volume flow rate, viscosity coefficient and tube length, and inversely proportional to the 4th power of the tube diameter. It is suitable for Newtonian fluids that are incompressible, do not have acceleration, laminar flow and are longer than the pipe diameter [4,5,6]. But blood is not fluid, and it is not laminar, and the pulmonary blood vessels are also contractible. Therefore, in clinical work, although the PVR formula is commonly used to evaluate pulmonary vascular disease, it is only a static index and has many influencing factors, so clinicians still need to interpret it accurately. This article reviews the application value of PVR in assessing the condition of PAH patients.

PVR and pathophysiology of PAH

The increase in PVR is closely related to the occurrence and development of PAH. From a pathophysiological point of view, PAH is a type of cardiopulmonary disease that can affect the arterial, venous circulation and right ventricle of the lung. Due to continuous vasoconstriction, excessive pulmonary vascular remodeling, and in situ thrombosis lead to an increase in PVR, which eventually can lead to right heart failure and even death [7, 8]. However, the influencing factors that lead to the acceleration or deterioration of PAH are still unclear, and may be related to genetics and the combined effects of multiple influencing factors. The influencing factors mainly include the process of vasoconstriction and promotion of remodeling, inflammation, vasoactive molecules, anti-apoptosis, and autoimmune mediators, as well as the interaction of cells and cells, cells and substrates, etc. [9].

From a pathological point of view, PAH is a progressive pulmonary vasculature disease, which is mainly characterized by the proliferation of various types of vascular wall cells (including endothelial cells, smooth muscle cells and fibroblasts) and then develops into a wide range of pulmonary vascular remodeling, which ultimately leads to an increase in PVR [10,11,12,13]. The increase in PVR is mainly caused by pulmonary artery contraction and complex arterial damage. Among them, pulmonary artery contraction damage includes media hypertrophy and intima and adventitia thickening, which may be related to the imbalance of different types of cell proliferation and apoptosis in the blood vessel wall. However, complex arterial damage is manifested as plexiform lesions, dilated lesions and arteritis. These changes are considered to be signs of the rapid progress of PAH [14, 15].

PVR on diagnostic value of PAH

The diagnosis and classification of PAH are complicated and mainly rely on hemodynamic indicators. Right-sided heart catheterization (RHC) is the "gold standard" for the diagnosis of PAH, and it is also an important means of differential diagnosis, evaluation of the condition and treatment effect. As one of hemodynamic diagnostic indicators, PVR has important value. PVR comes from calculations, PVR = (mPAP-PAWP)/CO, where mPAP is the mean pulmonary artery pressure, PAWP is the pulmonary arteriole wedge pressure, and CO is the cardiac output.

PVR on hemodynamic classification of PH

Pulmonary hypertension is defined as mPAP ≥ 25 mmHg (1 mmHg = 0.133 kPa) measured by the RHC at sea level and resting (Table 1). Including precapillary, postcapillary and mixed pulmonary hypertension (pulmonary artery and pulmonary vein pressure can be increased) [1]. Precapillary pulmonary hypertension includes PAH pulmonary hypertension caused by respiratory diseases and/or hypoxia; pulmonary hypertension caused by chronic pulmonary artery obstruction and pulmonary hypertension caused by unknown causes. The hemodynamics of precapillary pulmonary hypertension were defined as mPAP ≥ 25 mmHg, PAWP ≤ 15 mmHg and PVR > 3 wood units measured by RHC. Postcapillary pulmonary hypertension refers to pulmonary hypertension caused by left heart disease and pulmonary hypertension caused by unknown factors. The hemodynamics of postcapillary pulmonary hypertension is defined as the RHC measuring mPAP ≥ 25 mmHg, PAWP > 15 mmHg, in which simple postcapillary pulmonary hypertension PVR ≤ 3 wood units, mixed postcapillary pulmonary hypertension PVR > 3 wood units. Simonneau and Montani et al. [16] proposed a new definition of pulmonary hypertension hemodynamics. It is recommended to change mPAP ≥ 25 mmHg to ≥ 20 mmHg, and other indicators remain unchanged. Among them, mPAP is defined as a mild increase in 21–24 mmHg. PVR > 3 wood units, although relatively conservative, can more accurately diagnose precapillary and postcapillary pulmonary hypertension, and can distinguish increased pulmonary artery pressure caused by pulmonary vascular disease or increased PAWP. Thenappan et al. [17] found that compared with patients with PAH, patients with pulmonary hypertension caused by left heart disease had lower mPAP and PVR, higher CO, and enlarged left atrium. Studies on pulmonary hypertension caused by respiratory diseases showed that when the pulmonary artery pressure increased significantly, the PVR also increased significantly [18, 19]. Even if the pulmonary artery pressure increased only slightly, the increase in PVR would be greater than 3 wood units. Similar to the results of a prospective study on chronic thromboembolic pulmonary hypertension [20]. The increase in PVR is mainly due to alveolar hypoxia or thrombotic obstruction leading to vasoconstriction or pulmonary vascular remodeling. However, some studies have shown that PVR has no significant difference in responsiveness to hypoxia or hyperoxia in a short period of time [21, 22], and the significant increase in PVR may be related to a decrease in CO or other diseases. In short, PVR is an important indicator for diagnosing PAH, and we need to accurately interpret the data measured by the RHC.

Table 1 PVR on hemodynamic classification of PH

PVR on preoperative assessment of PAH related to congenital heart disease

PAH associated with congenital heart disease is an important subtype of PAH, a type of precapillary pulmonary hypertension, and the most common type of PAH patients in China. Clinical classification of PAH associated with congenital heart disease as follows: (1) Eisenmenger syndrome: including all large defects inside and outside the heart, starting from systemic to pulmonary shunt, and then reversal (pulmonary circulation to systemic shunt) or bidirectional shunt as the PVR is severely elevated, and the patient has cyanosis, secondary to polycythemia and multiple organ involvement. (2) Systemic to pulmonary shunt congenital heart disease: It can be divided into two types: correctable and uncorrectable type. The correctable type refers to a moderate to large defect, PVR is slightly to moderately elevated, and shunts from systemic circulation to pulmonary circulation are still present, and cyanosis is not the main feature. Uncorrectable type means that there is currently no indication for interventional closure and surgical repair. (3) PAH with small defects: small defects combined with a significant increase in PVR (small defects refer to adult ventricular septal defect < 1 cm and atrial septal defect < 2 cm measured by echocardiography), and there is an increase in PVR that cannot be explained by the defect. The clinical features are similar to idiopathic pulmonary hypertension, and such defects cannot be closed. (4) PAH after correction of congenital heart disease: PAH persists after interventional closure or surgical repair of congenital heart disease, or PAH reappears after several months or years, and the condition of such patients often worsens [1, 2].

According to the European Adult Congenital Heart Disease Survey, the overall prevalence of PAH in adult patients with congenital heart disease is 4–28%, and Eisenmenger syndrome is 1–6%. Among all patients with open defects, 34% of patients with atrial septal defect and 28% of patients with ventricular septal defect have PAH, and the corresponding proportions of patients with closed defects are 12% and 13% respectively [23, 24]. PAH associated with congenital heart disease is different from other types of PAH, and has early reversible and late irreversible characteristics; timely closing of the shunt channel can make the pulmonary vessel morphology and hemodynamics normal [25,26,27]. In addition to considering the nature and size of the defect, the timing of closing the defect and preoperative hemodynamics are also critical. Studies have shown that PVR can become normal when the defect is closed by surgery within 1 year old; PVR may decline after the operation when it is over 2 years old, but it may not return to normal levels [27]. In clinical work, for patients with shunts, the Fick method is often used to measure the pulmonary circulation (Qp)/systemic circulation (Qs) blood flow, and calculate the PVR after quantifying the shunt to assess the feasibility of surgery. Because when there is a large systemic circulation to the pulmonary circulatory shunt, the increase in pulmonary blood flow causes a significant increase in pulmonary artery pressure, and the increase in PVR may not be significant. A retrospective study found that when the baseline value is PVR ≥ 5 wood units, pulmonary vascular resistance index (PVRi) ≥ 6 wood units·m2, and the PVR/system-wide vascular resistance ratio ≥ 0.33, after closing the defect of patients, PAH is more likely to occur in the late follow-up stage [28], but this conclusion needs further verification.

At present, the criteria for judging the feasibility of surgery for congenital heart disease combined with PAH are not uniform. According to the available data, the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) Guidelines for Diagnosis and Treatment of Pulmonary Hypertension proposes the criteria for shut-off systemic-pulmonary shunt based on PVR (Table 2): PVR < 2.3 wood units, PVRi < 4 wood units·m2, it is recommended to close the defect; when PVR > 4.6 wood units, PVRi > 8 wood units·m2, it is not recommended to close the defect; PVR is 2.3 ~ 4.6 wood units, PVRi is 4–8 wood units·m2 is the “gray zone”, which requires individualized assessment in a tertiary hospital [1]. For patients in the "gray zone", it is suggested that the defect can be closed when the PVR is reduced to an acceptable level by treating PAH [29, 30], but considering the impact on the right ventricle, we believe that the existing data does not yet support the concept of "treatment to closing defects".

Table 2 PVR on surgery criteria of PAH related to congenital heart disease

PVR measured by echocardiography on PAH

The diagnosis and treatment process of PAH is becoming standardized, and echocardiography as its non-invasive diagnostic tool can initially screen patients with PAH. It is believed that the use of echocardiography to assess pulmonary artery pressure is reliable. In the absence of pulmonary outflow tract obstruction, the tricuspid regurgitation peak velocity (TRV) is linearly positively correlated with mPAP and the pulmonary artery systolic pressure (sPAP) measured by RHC; while the acceleration time of the right ventricular outflow tract is linearly negatively correlated with sPAP and mPAP [31, 32]. In clinical practice, TRV is mostly used to assess right ventricular systolic pressure (RVSP). On the premise of excluding right ventricular outflow tract obstruction, sPAP is equivalent to RVSP plus right atrial pressure (RAP), RVSP = 4 × (TRV)2, sPAP = 4 × (TRV)2 + RAP [33, 34]. Echocardiography can also be used to assess PVR, and PVR = TRV (m/s)/TVIRVOT (cm), and the time-velocity integral of the right ventricular outflow tract short for TVIRVOT [35,36,37,38]. At present, these assessment methods are based on the recognition that PVR is directly related to pressure changes and negatively related to pulmonary blood flow. Although different calculation methods have proved that there is a certain correlation between the echocardiographic assessment of PVR and the PVR calculated by RHC, further research is needed to confirm. PVR not only helps to distinguish the increase in mPAP caused by increased pulmonary blood flow (such as hyperthyroidism, anemia, obesity, etc.), but also helps to distinguish PAH patients with severe or worsening clinical symptoms but not obvious changes in mPAP [31]. Studies [39, 40] have found that echocardiography may underestimate or overestimate sPAP, and mPAP cannot be directly measured, nor can it indicate whether sPAP is related to pulmonary vascular disease. Therefore, it is not possible to formulate a treatment plan based on clinical manifestations and echocardiographic examination results alone, and RHC examination must be performed.

PVR on PAH risk stratification, prognosis assessment and early diagnosis

PVR on risk stratification of PAH

The diagnosis of PAH relies on hemodynamic data, but the evaluation of the condition and prognosis requires reference to multiple clinical indicators. The main indicators in the currently recommended risk stratification table include the World Health Organization (WHO) cardiac function classification, 6-min walking distance (6MWD), N-terminal pro-B-type natriuretic peptide (NT-proBNP), right atrial pressure (RAP), heart index (CI), and mixed venous oxygen saturation (SVO2). Studies have shown that PVR and the above indicators are correlated at baseline and 6 months after treatment [41, 42]. Studies on the treatment of connective tissue-related PAH with riociguat showed that the improvement of PVR is consistent with the improvement of 6MWD, WHO cardiac function classification and CI [43, 44]. Simpson et al. [45] related research results on biomarkers showed that NT-proBNP is correlated with RAP, mPAP, cardiac output (CO), and PVR. Although PVR is not included in the risk stratification table, it has a certain correlation with PAH risk stratification related indicators; at the same time, the risk stratification table is only applicable to adult PAH; however, studies have shown that PVR is in adolescents and children similar to adults, the PVR of adolescents is usually less than 2 wood units [46, 47].

PVR on prognosis of PAH patients

We usually guide and evaluate the treatment and prognosis of PAH patients based on clinical manifestations, echocardiography, and risk stratification related indicators. Most studies have confirmed that CO or CI and RAP at baseline can be used as prognostic factors for PAH [48, 49], while the value of routinely measured mPAP and PVR for prognosis has not yet reached a consensus. Studies on the 1-year survival rate of PAH patients show that mPAP is not an independent predictor of PAH prognosis, while elevated RAP and PVR > 32 wood units are its independent predictors [50]. However, a study [51] on the prognostic value of hemodynamic indicators in PAH patients showed that all-cause death and lung transplantation were used as the research endpoints, and age, gender (male), etiology (idiopathic pulmonary hypertension), New York Heart Association cardiac function classification and 6MWD are independent predictors, and have nothing to do with baseline hemodynamic indicators.

PVR on early diagnosis of PAH

PVR can be used for early diagnosis of PAH. PVR > 3 wood units, although it is of great significance for the diagnosis of precapillary pulmonary hypertension. However, early CO in many patients tends to be normal and rarely shows PVR > 3 wood units, which cannot meet the diagnosis of precapillary pulmonary hypertension and is not conducive to the early diagnosis of PAH. A study on the hemodynamic characteristics and survival rate of patients with systemic sclerosis (SSc), in addition to showing that PVR and 6MWD can be used as independent predictors of the prognosis of PAH patients, it is also recommended to adjust the PVR cutoff value ≥ 2 wood unit [52]. Studies have found that PVR ≥ 2 wood units are associated with pulmonary vascular disease and the survival rate of patients is significantly reduced, while PVR ≥ 2 wood units are more suitable for early diagnosis of SSc-PAH in high-risk populations. Previous studies [53, 54] have found that dynamic PVR can be used as an independent predictor of SSc-PAH, but its predictive value needs to consider disease classification or progression. PVR is calculated based on the data measured by RHC in the resting state, but dynamic PVR is expressed by the slope of the multipoint mPAP-flow diagram, which can better display the PVR situation, but the clinical significance is still unclear [55, 56].

Influencing factors of PVR

PAH patients mainly die of right heart failure, and right heart failure is different from right ventricular dysfunction (RVD). Right heart failure is a clinical syndrome with symptoms and signs of heart failure caused by RVD. The most common cause of chronic right heart failure is pulmonary hypertension caused by left heart failure, leading to increased right ventricular afterload [57]. RVD is manifested as an abnormal structure or function of the right ventricle, and right ventricular systolic dysfunction (RVSD) is an important predictor of the prognosis of heart failure. Studies have shown that in addition to heart failure with reduced ejection fraction, RVSD is also more common in heart failure with preserved ejection fraction and has a poor prognosis [58]. Studies have confirmed that in patients with heart failure with preserved ejection fraction, the baseline level of PVR in RVSD patients is significantly increased, the right ventricular ejection fraction is related to PVR but not mPAP, and both RVSD and PVR have an impact on the prognosis [59, 60]. Badagliacca et al. [61] found that PVR reduction is the only determinant of right ventricular reversal remodeling, and proposed that the reason why PVR improvement cannot be an independent predictor of prognosis may be because its reduction is only a driving factor for the improvement of right ventricular structure and function.

Roca et al. [62] in the study of the effect of reduced PVR on the left and right ventricular changes in PAH patients found that baseline PVR was significantly related to the degree of longitudinal muscle fiber damage in the free wall of the right ventricle, but not with the left ventricular changes. The decrease in PVR at 24 weeks of treatment was related to the improvement of the left and right ventricles. Right heart failure is the main cause of death in PAH patients, and the increase in right ventricular afterload is mainly determined by the pressure-flow relationship. However, PVR cannot fully explain the right ventricular afterload, because it ignores the impact of pulsatile load [63]. As early as 1682, William Harvey discovered the interaction between the right ventricle and the pulmonary circulation, but then the concept of "right ventricle-pulmonary artery" coupling was not taken seriously. In recent years, with the improvement of PAH awareness, people have begun to pay attention to the overall concept of right ventricle-pulmonary artery. It has also been proposed that pulmonary vascular impedance can more accurately describe the pressure-flow relationship, because the combined effect of PVR and total pulmonary artery compliance (PCa) is considered, but there are still difficulties in its measurement and interpretation [3]. Ideally, we think that the two are separable indicators, that is, when the PVR increases or decreases in the pulmonary circulation, the total PCa decreases or increases accordingly. However, some studies have found that PVR is closely related to age. Although PVR is low in elderly patients, PCa does not increase correspondingly, and it is believed that PCa has a greater impact on its prognostic value [64, 65]. A study [66] found that in patients with precapillary pulmonary hypertension, PVR may be overestimated according to the formula calculation, because the average lung blood flow is represented by the transpulmonary pressure difference, that is, mPAP minus the pressure at the average downstream zero flow; generally use PAWP instead, but the actual PAWP is less than the average downstream pressure at zero flow.

In addition to calculation errors, there are many other factors that affect PVR. PVR is negatively correlated with total PCa and also negatively correlated with pulmonary vessel volume [67]. According to the definition of PVR, it is related to blood viscosity, that is, hematocrit can also affect PVR [68]. At the same time, with the understanding of exercise-related pulmonary hypertension, it is confirmed that PVR is different between rest and exercise [69]. Some researchers also believe that preterm birth may increase PVR. Studies have found that young people with a history of preterm birth may have pulmonary vascular disease, which is manifested by increased mPAP, increased PVR during rest and exercise (pulmonary capillary bed stiffness), decreased CO during exercise and decreased right ventricular systolic function [70]. Some researchers have found that air pollution may also increase PVR by reducing CO [71]. In short, a more comprehensive understanding of the influencing factors of PVR helps to accurately interpret it.

Conclusions and outlook

In summary, PAH is a rare but serious pulmonary vascular disease. As one of the diagnostic indicators of PAH hemodynamics, PVR plays an irreplaceable role in the diagnosis and clinical classification of precapillary pulmonary hypertension. At the same time, PVR and PAH risk stratification indicators have a certain correlation, and also have important value in the prognosis and early diagnosis of some PAH. However, it is a static index and does not include pulsatile load. It is not the best index for evaluation of right ventricular afterload. Pulmonary circulation is different from systemic circulation because it is a vascular system with low resistance and high compliance. Considering the heterogeneity of PAH, we should not only have a overall concept of "right ventricle-pulmonary artery", but also explore the value of "pulmonary vascular impedance". I believe that with the development of medical technology, we will have a better understanding of PAH.

Availability of data and materials

All data can be contacted with the authors.



Pulmonary arterial hypertension


Pulmonary hypertension


Pulmonary vascular resistance


Right-sided heart catheterization


Mean pulmonary artery pressure


Pulmonary arteriole wedge pressure


Cardiac output


Pulmonary circulation


Systemic circulation


Pulmonary vascular resistance index


European Society of Cardiology


European Respiratory Society


Tricuspid regurgitation peak velocity


Pulmonary artery systolic pressure


Right ventricular systolic pressure


Right atrial pressure


Time-velocity integral of the right ventricular outflow tract


World Health Organization


6-Min walking distance


N-terminal pro-B-type natriuretic peptide


Heart index

SVO2 :

Mixed venous oxygen saturation


Systemic sclerosis


Right ventricular dysfunction


Right ventricular systolic dysfunction


Pulmonary artery compliance


  1. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.

    Article  PubMed  Google Scholar 

  2. A.E. Lammers, C. Apitz, P. Zartner, A. Hager, K.O. Dubowy, G. Hansmann, Diagnostics, monitoring and outpatient care in children with suspected pulmonary hypertension/paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK, Heart 102 (2016) Suppl 2:ii1–13.

  3. Clark A, Tawha M. Pulmonary vascular dynamics. Compr Physiol. 2019;9(3):1081–100.

    Article  PubMed  Google Scholar 

  4. Shimoda LA. Overview: pulmonary vascular function in health and disease. J Physiol. 2019;597(4):973–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Brittain EL, Thennapan T, Maron BA, Chan SY, Austin ED, Spiekerkoetter E, et al. Update in pulmonary vascular disease 2016 and 2017. Am J Respir Crit Care Med. 2018;198(1):13–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hemnes AR, Beck GJ, Newman JH, Abidov A, Aldred MA, Barnard J, et al. PVDOMICS: a multi-center study to improve understanding of pulmonary vascular disease through ohenomics. Circ Res. 2017;121(10):1136–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Tuder RM, Archer SL, Dorfmüller P, Erzurum SC, Guignabert C, Michelakis E, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D4-12.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019;53(1):1801887.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation. 2010;121(18):2045–66.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Nickel NP, Spiekerkoetter E, Gu M, Li CG, Li H, Kaschwich M, et al. Elafin reverses pulmonary hypertension via caveolin-1-dependent bone morphogenetic protein signaling. Am J Respir Crit Care Med. 2015;191(11):1273–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Tian W, Jiang X, Sung YK, Shuffle E, Wu TH, Kao PN, et al. Phenotypically silent bone morphogenetic orotein receptor 2 mutations predispose rats to inflammation-induced pulmonary arterial hypertension by enhancing the risk for neointimal transformation. Circulation. 2019;140(17):1409–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Calvier L, Boucher P, Herz J, Hansmann G. LRP1 deficiency in vascular SMC leads to pulmonary arterial hypertension that is reversed by PPARγ activation. Circ Res. 2019;124(12):1778–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ventetuolo CE, Aliotta JM, Braza J, Chichger H, Dooner M, McGuirl D, et al. Culture of pulmonary artery endothelial cells from pulmonary artery catheter balloon tips: considerations for use in pulmonary vascular disease. Eur Respir J. 2020;55(3):1901313.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. G.G. Pietra, F. Capron, S. Stewart, O. Leone, M. Humbert, I.M. Robbins, et al., Pathologic assessment of vasculopathies in pulmonary hypertension, J. Am. Coll. Cardiol. 43 (12 Suppl S) (2004) 25S–32S.

  15. Stewart S, Rassl D. Advances in the understanding and classification of pulmonary hypertension. Histopathology. 2009;54(1):104–16.

    Article  PubMed  Google Scholar 

  16. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Thenappan T, Shah SJ, Gomberg-Maitland M, Collander B, Vallakati A, Shroff P, et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2011;4(3):257–65.

    Article  PubMed  Google Scholar 

  18. Calcaianu G, Canuet M, Schuller A, Enache I, Chaouat A, Kessler R. Pulmonary arterial hypertension-specific drug therapy in COPD patients with severe pulmonary hypertension and mild-to-moderate airflow limitation. Respiration. 2016;91(1):9–17.

    Article  CAS  PubMed  Google Scholar 

  19. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducoloné A, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(2):189–94.

    Article  PubMed  Google Scholar 

  20. Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011;124(18):1973–81.

    Article  PubMed  Google Scholar 

  21. Groth A, Saxer S, Bader PR, Lichtblau M, Furian M, Schneider SR, et al. Acute hemodynamic changes by breathing hypoxic and hyperoxic gas mixtures in pulmonary arterial and chronic thromboembolic pulmonary hypertension. Int J Cardiol. 2018;270:262–7.

    Article  PubMed  Google Scholar 

  22. Ulrich S, Hasler ED, Saxer S, Furian M, Müller-Mottet S, Keusch S, et al. Effect of breathing oxygen-enriched air on exercise performance in patients with precapillary pulmonary hypertension: randomized, sham-controlled cross-over trial. Eur Heart J. 2017;38(15):1159–68.

    Article  CAS  PubMed  Google Scholar 

  23. M.GJ Duffels, P.M Engelfriet, R.MF Berger, R.LE van Loon, E. Hoendermis, J.WJ Vriend, et al., Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry, Int. J. Cardiol. 120 (2) (2007) 198–204.

  24. Engelfriet PM, Duffels MGJ, Möller T, Boersma E, Tijssen JGP, Thaulow E, et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart. 2007;93(6):682–7.

    Article  PubMed  Google Scholar 

  25. van der Feen DE, Bartelds B, de Boer RA, Berger RMF. Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease. Eur Heart J. 2017;38(26):2034–41.

    Article  PubMed  CAS  Google Scholar 

  26. Beghetti M, Galiè N. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;53(9):733–40.

    Article  PubMed  Google Scholar 

  27. D’Alto M, Mahadevan VS. Pulmonary arterial hypertension associated with congenital heart disease. Eur Respir Rev. 2012;21(126):328–37.

    Article  PubMed  Google Scholar 

  28. M. D′Alto, E. Romeo, P. Argiento, A. Correra, G. Santoro, G. Gaio, et al., Hemodynamics of patients developing pulmonary arterial hypertension after shunt closure, Int. J. Cardiol. 168 (4) (2013) 3797–801.

  29. Dimopoulos K, Wort SJ, Gatzoulis MA. Pulmonary hypertension related to congenital heart disease: a call for action. Eur Heart J. 2014;35(11):691–700.

    Article  PubMed  Google Scholar 

  30. D’Alto M, Diller GP. Pulmonary hypertension in adults with congenital heart disease and Eisenmenger syndrome: current advanced management strategies. Heart. 2014;100(17):1322–8.

    Article  PubMed  Google Scholar 

  31. E. Bossone, A. D′Andrea, M. D′Alto, R. Citro, P. Argiento, F. Ferrara, et al., Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis, J. Am. Soc. Echocardiogr. 26 (1) (2013) 1–14.

  32. Bossone E, Bodini BD, Mazza A, Allegra L. Pulmonary arterial hypertension: the key role of echocardiography. Chest. 2005;127(5):1836–43.

    Article  PubMed  Google Scholar 

  33. L.G Rudski, W.W Lai, J. Afilalo, L. Hua, M.D Handschumacher, K. Chandrasekaran, et al., Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography, J. Am. Soc. Echocardiogr. 23 (7) (2010) 685–713; quiz 786–788.

  34. Howard LS, Grapsa J, Dawson D, Bellamy M, Chambers JB, Masani ND, et al. Echocardiographic assessment of pulmonary hypertension: standard operating procedure. Eur Respir Rev. 2012;21(125):239–48.

    Article  PubMed  Google Scholar 

  35. A.E Abbas, F D. Fortuin, N.B Schiller, C.P Appleton, C.A Moreno, S.J Lester, A simple method for noninvasive estimation of pulmonary vascular resistance, J. Am. Coll. Cardiol. 41 (6) (2003) 1021–7.

  36. Rajagopalan N, Simon MA, Suffoletto MS, Shah H, Edelman K, Mathier MA, et al. Noninvasive estimation of pulmonary vascular resistance in pulmonary hypertension. Echocardiography. 2009;26(5):489–94.

    Article  PubMed  Google Scholar 

  37. L.M Wright, N. Dwyer, D. Celermajer, L. Kritharides, T.M Marwick, Follow-up of pulmonary hypertension with echocardiography, J.A.C.C. Cardiovasc. Imaging 9 (6) (2016) 733–746.

  38. Abbas AE, Franey LM, Marwick T, Maeder MT, Kaye DM, Vlahos AP, et al. Noninvasive assessment of pulmonary vascular resistance by Doppler echocardiography. J Am Soc Echocardiogr. 2013;26(10):1170–7.

    Article  PubMed  Google Scholar 

  39. Rich JD, Shah SJ, Swamy RS, Kamp A, Rich S, et al. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest. 2011;139(5):988–93.

    Article  PubMed  Google Scholar 

  40. Groh GK, Levy PT, Holland MR, Murphy JJ, Sekarski TJ, Myers CL, et al. Doppler echocardiography inaccurately estimates right ventricular pressure in children with elevated right heart pressure. J Am Soc Echocardiogr. 2014;27(2):163–71.

    Article  PubMed  Google Scholar 

  41. Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani HA, et al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. Eur Heart J. 2017;38(15):1147–55.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani HA, Channick RN, et al. Macitentan improves health-related quality of life for patients with pulmonary arterial hypertension: results from the randomized controlled SERAPHIN trial. Chest. 2017;151(1):106–18.

    Article  PubMed  Google Scholar 

  43. Humbert M, Coghlan JG, Ghofrani HA, Grimminger F, He JG, Riemekasten G, et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis. 2017;76(2):422–6.

    Article  CAS  PubMed  Google Scholar 

  44. Ghofrani HA, Grimminger F, Grünig E, Huang Y, Jansa P, Jing ZC, et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med. 2016;4(5):361–71.

    Article  CAS  PubMed  Google Scholar 

  45. Simpson CE, Damico RL, Hassoun PM, Martin LJ, Yang J, Nies MK, et al. Noninvasive prognostic biomarkers for left-sided heart failure as predictors of survival in pulmonary arterial hypertension. Chest. 2020;157(6):1606–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Agnoletti G, Gala S, Ferroni F, Bordese R, Appendini L, Napoleone CP, et al. Endothelin inhibitors lower pulmonary vascular resistance and improve functional capacity in patients with Fontan circulation. J Thorac Cardiovasc Surg. 2017;153(6):1468–75.

    Article  CAS  PubMed  Google Scholar 

  47. Derk G, Houser L, Miner P, Williams R, Moriarty J, Finn P, et al. Efficacy of endothelin blockade in adults with Fontan physiology. Congenit Heart Dis. 2015;10(1):E11-16.

    Article  PubMed  Google Scholar 

  48. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156–63.

    Article  PubMed  Google Scholar 

  49. Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, et al. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken). 2014;66(3):489–95.

    Article  Google Scholar 

  50. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2):164–72.

    Article  PubMed  Google Scholar 

  51. Weatherald J, Boucly A, Chemla D, Savale L, Peng M, Jevnikar M, et al. Prognostic value of follow-up hemodynamic variables after initial management in pulmonary arterial hypertension. Circulation. 2018;137(7):693–704.

    Article  PubMed  Google Scholar 

  52. Xanthouli P, Jordan S, Milde N, Marra A, Blank N, Egenlauf B, et al. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. Ann Rheum Dis. 2020;79(3):370–8.

    Article  PubMed  Google Scholar 

  53. Gabriels C, Lancellotti P, Van De Bruaene A, Voilliot D, De Meester P, Buys R, et al. Clinical significance of dynamic pulmonary vascular resistance in two populations at risk of pulmonary arterial hypertension. Eur Heart J Cardiovasc Imaging. 2015;16(5):564–70.

    Article  PubMed  Google Scholar 

  54. Voilliot D, Magne J, Dulgheru R, Kou S, Henri C, Laaraibi S, et al. Determinants of exercise-induced pulmonary arterial hypertension in systemic sclerosis. Int J Cardiol. 2014;173(3):373–9.

    Article  PubMed  Google Scholar 

  55. Argiento P, Vanderpool RR, Mulè M, Russo MG, D’Alto M, Bossone E, et al. Exercise stress echocardiography of the pulmonary circulation: limits of normal and sex differences. Chest. 2012;142(5):1158–65.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Vriz O, Argiento P, D’Alto M, Ferrara F, Vanderpool R, Naeije R, et al. Increased pulmonary vascular resistance in early stage systemic hypertension: a resting and exercise stress echocardiography study. Can J Cardiol. 2015;31(4):537–43.

    Article  PubMed  Google Scholar 

  57. Konstam MA, Kiernan MS, Bernstein D, Bozkurt B, Jacob M, Kapur NK, et al. Evaluation and management of right-sided heart failure: a scientific statement from the American Heart Association. Circulation. 2018;137(20):e578-622.

    Article  PubMed  Google Scholar 

  58. Mohammed SF, Hussain I, AbouEzzeddine OF, Takahama H, Kwon SH, Forfia P, et al. Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation. 2014;130(25):2310–20.

    Article  PubMed  PubMed Central  Google Scholar 

  59. L. Bosch, C.SP Lam, L. Gong, S.P. Chan, D. Sim, D. Yeo, et al., Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction, Eur. J. Heart Fail. 19 (12) (2017) 1664–1671.

  60. Aschauer S, Kammerlander AA, Zotter-Tufaro C, Ristl R, Pfaffenberger S, Bachmann A, et al. The right heart in heart failure with preserved ejection fraction: insights from cardiac magnetic resonance imaging and invasive haemodynamics. Eur J Heart Fail. 2016;18(1):71–80.

    Article  PubMed  Google Scholar 

  61. Badagliacca R, Poscia R, Pezzuto B, Papa S, Reali M, Pesce F, et al. Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension. J Heart Lung Transplant. 2017;S1053–2498(17):32041–7.

    Google Scholar 

  62. Roca GQ, Campbell P, Claggett B, Vazir A, Quinn D, Solomon SD, et al. Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension. Eur J Heart Fail. 2015;17(1):63–73.

    Article  Google Scholar 

  63. K.S Hunter, P.F. Lee, C.J Lanning, DD. Lvy, KS. Kirby, L.R Claussen, et al., Pulmonary vascular input impedance is a combined measure of pulmonary vascular resistance and stiffness and predicts clinical outcomes better than pulmonary vascular resistance alone in pediatric patients with pulmonary hypertension, Am. Heart J. 155 (1) (2008) 166–174.

  64. DesJardin JT, Kolaitis NA, Kime N, Kronmal RA, Benza RL, Elwing JM, et al. Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: baseline results from the Pulmonary Hypertension Association Registry. J Heart Lung Transpl. 2020;39(9):945–53.

    Article  Google Scholar 

  65. N.A Kolaitis, R.T Zamanian, V.A de Jesus Perez, D.B Badesch, R.L Benza, C.D Burger, et al., Clinical differences and outcomes between methamphetamine-associated and idiopathic pulmonary arterial hypertension in the Pulmonary Hypertension Association Registry, Ann. Am. Thorac. Soc. 18 (4) (2021) 613–22.

  66. D. Chemla, E.MT Lau, Y. Papelier, P. Attal, P. Hervé, Pulmonary vascular resistance and compliance relationship in pulmonary hypertension, Eur. Respir. J. 46 (4) (2015) 1178–89.

  67. Newman JH, Brittain EL, Robbins IM, Hemnes AR. Effect of acute arteriolar vasodilation on capacitance and resistance in pulmonary arterial hypertension. Chest. 2015;147(4):1080–5.

    Article  PubMed  Google Scholar 

  68. J.IE Hoffman, Pulmonary vascular resistance and viscosity: the forgotten factor, Pediatr. Cardiol. 32 (5) (2011) 557–561.

  69. Kovacs G, Herve P, Barbera JA, Chaouat A, Chemla D, Condliffe R, et al. An official European Respiratory Society statement: pulmonary haemodynamics during exercise. Eur Respir J. 2017;50(5):1700578.

    Article  PubMed  Google Scholar 

  70. Goss KN, Beshish AG, Barton GP, Haraldsdottir K, Levin TS, Tetri LH, et al. Early pulmonary vascular disease in young adults born preterm. Am J Respir Crit Care Med. 2018;198(12):1549–58.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Wauters A, Vicenzi M, De Becker B, Riga JP, Esmaeilzadeh F, Faoro V, et al. At high cardiac output, diesel exhaust exposure increases pulmonary vascular resistance and decreases distensibility of pulmonary resistive vessels. Am J Physiol Heart Circ Physiol. 2015;309(12):H2137-2144.

    Article  CAS  PubMed  Google Scholar 

Download references


The authors would like to thank Dr. Jianming Chen and Dr. Ying Jin for their assistance for editorial help with this manuscript.



Author information

Authors and Affiliations



JD wrote this manuscript. The author read and approved the final manuscript.

Corresponding author

Correspondence to Jianying Deng.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that there are no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deng, J. Clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension. J Cardiothorac Surg 16, 311 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: